Oxford Cancer Biomarkers (OCB) is a company that develops and commercializes biomarker tests. It offers such products as ToxNav that predicts individuals' propensity to develop life-threatening adverse reactions from 5FU/capecitabine chemotherapy, as well as ColoProg, a digital pathology test for the recurrence of stage II tumours. Additionally, the company provides ColoPredict, a mouth swab that helps identify whether individuals are at increased risk of developing colorectal cancer.